With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

At a time when fried chicken sandwiches, cheeseburger and fries, and pizza dominate the American restaurant landscape, a ...

Plus: How AI propelled Nvidia up the list and other insights from this year's survey of corporate reputations.

First Financial Bancorp, a financial holding company with a rich heritage spanning 160 years, presented its investor ...

It's up to each owner to assess what options make most sense for their individual situation, says pet owner and co-founder of ...

Shares of Tectonic plummeted 41% Tuesday following news that a similar drug developed by Eli Lilly (NYSE: LLY) for chronic ...

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

Eli Lilly And Co (LLY) stock saw a modest uptick, ending the day at $808.17 which represents a slight increase of $22.76 or 2.90% from the prior close of $785.41. The stock opened at $780.91 and ...

The discovery was made when a local amateur fossil hunter Peter Bennicke found some unusual fragments the Cliffs of Stevns, a ...

Citi analyst Geoff Meacham lowered the firm’s price target on Eli Lilly to $1,190 from $1,250 and keeps a Buy rating on the shares. Ahead of ...